Michel Azizi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michel Azizi has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
J. Menard
2 shared publicationsJoël Ménard
2 shared publications- Pierre-François Plouin
Hypertension Unit, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou. Paris, FRANCE
2 shared publications S. Peyrard
2 shared publications- Ales Linhart
2nd Department of Internal Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital , Prague
1 shared publication Allan Goldberg
1 shared publication
Latest Publications
- 1 August 2000
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 18 (8) , 1139-1147
Pilot study of combined blockade of the renin–angiotensin system in essential hypertensive patients
Additive hemodynamic effects of combined blockade of the renin–angiotensin system by an angiotensin I converting enzyme inhibitor and an angiotensin II antagonist have been observed in sodium-depleted normotensive volunteers and in patients with congestive heart failure. To investigate whether the same additive hemodynamic effects occur in patients with hypertension and to verify the safety of such an approach. Multicenter, randomized, double-blind, parallel-group, pilot study. 177 patients with mild-to-moderate hypertension [diastolic blood pressure (DBP): 95–115 mmHg after a 4-week placebo run-in period] were included in the study. Combination therapy consisting of 50 mg losartan daily and 10 mg enalapril daily was administered for 6 weeks. The effects of this therapeutic regimen was compared with similar groups of patients who received either 50 mg losartan daily or 10 mg enalapril daily 24-hour ambulatory mean DBP and clinic DBP measured at trough after 6 weeks of treatment. 24-hour ambulatory mean DBP did not significantly differ between treatment groups although the combination tended to lower BP more. The combination therapy was more effective on clinic DBP measured at trough than was losartan by 3.2 mmHg [confidence interval (95%, CI) 0.7–5.7 mmHg, P = 0.012], and more effective than enalapril by 4.0 mmHg (95% CI, 1.5–6.4 mmHg, P = 0.002). In a subgroup of 28 patients, higher plasma active renin and angiotensin I levels during blockade by the combination therapy were observed. This finding confirmed that the combination of the two agents inhibited the renin–angiotensin system to a greater extent than did either agent alone. A combination of 10 mg enalapril daily and 50 mg losartan daily safely induces a supplementary, although modest, fall in clinic DBP in patients with mild-to-moderate essential hypertension.
- 1 August 2000
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 18 (8) , 1139-1147
Pilot study of combined blockade of the renin–angiotensin system in essential hypertensive patients
Additive hemodynamic effects of combined blockade of the renin–angiotensin system by an angiotensin I converting enzyme inhibitor and an angiotensin II antagonist have been observed in sodium-depleted normotensive volunteers and in patients with congestive heart failure. To investigate whether the same additive hemodynamic effects occur in patients with hypertension and to verify the safety of such an approach. Multicenter, randomized, double-blind, parallel-group, pilot study. 177 patients with mild-to-moderate hypertension [diastolic blood pressure (DBP): 95–115 mmHg after a 4-week placebo run-in period] were included in the study. Combination therapy consisting of 50 mg losartan daily and 10 mg enalapril daily was administered for 6 weeks. The effects of this therapeutic regimen was compared with similar groups of patients who received either 50 mg losartan daily or 10 mg enalapril daily 24-hour ambulatory mean DBP and clinic DBP measured at trough after 6 weeks of treatment. 24-hour ambulatory mean DBP did not significantly differ between treatment groups although the combination tended to lower BP more. The combination therapy was more effective on clinic DBP measured at trough than was losartan by 3.2 mmHg [confidence interval (95%, CI) 0.7–5.7 mmHg, P = 0.012], and more effective than enalapril by 4.0 mmHg (95% CI, 1.5–6.4 mmHg, P = 0.002). In a subgroup of 28 patients, higher plasma active renin and angiotensin I levels during blockade by the combination therapy were observed. This finding confirmed that the combination of the two agents inhibited the renin–angiotensin system to a greater extent than did either agent alone. A combination of 10 mg enalapril daily and 50 mg losartan daily safely induces a supplementary, although modest, fall in clinic DBP in patients with mild-to-moderate essential hypertension.
- 1 June 2000
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 18, S211-S212
NO INFLUENCE OF THE INSERTION/DELETION POLYMORPHISM OF THE ANGIOTENSIN I CONVERTING ENZYME GENE ON N-Acetyl-Ser-Asp-Lys-Pro METABOLISM
- 1 June 2000
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 18, S211-S212
NO INFLUENCE OF THE INSERTION/DELETION POLYMORPHISM OF THE ANGIOTENSIN I CONVERTING ENZYME GENE ON N-Acetyl-Ser-Asp-Lys-Pro METABOLISM
- 1 April 1999
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 17 (4) , 561-568
Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan
The variability of the blood pressure response to blockade of the angiotensin II type 1 receptor is influenced by renin status and pharmacokinetics and pharmacokinetic-Spharmacodynamic interactions. To compare the pharmacokinetic-pharmacodynamic interactions of two doses of an ester prodrug of a noncompetitive angiotensin II type 1 receptor antagonist, candesartan cilexetil, at 8 and 16 mg, with those of the reference angiotenisn II type 1 receptor blocker, losartan, at the standard dose (50 mg), in a human model that controls renin status. In a double-blind placebo-controlled crossover study, we compared the effects on renin and mean blood pressure over 24 h of single oral doses of candesartan cilexetil at 8 and 16 mg and losartan at 50 mg in 16 sodium-depleted normotensive subjects. The area under the curve (0–24 h) for plasma active renin did not differ significantly between 8 mg candesartan cilexetil and 50 mg losartan, but was significantly higher for 16 than for 8 mg candesartan cilexetil or for 50 mg losartan. The area under the curve (0–24 h) for the fall in mean blood pressure with 16 mg candesartan cilexetil (−2197 ± 96 mmHg/h) was significantly greater than that for placebo (−112 ± 81 mmHg/h; P < 0.05) but the difference was not statistically significant compared with either 8 mg candesartan cilexetil (−158 ± 95 mmHg/h) or 50 mg losartan (−144 ± 66 mmHg/h). The area under the curve (0–24 h) for the fall in mean blood pressure did not significantly differ between 8 mg candesartan cilexetil, 50 mg losartan and placebo. The area under the curve (0–24 h) for plasma active renin was significantly correlated to that for plasma levels of the active metabolite of losartan, EXP 3174 (r = 0.65, n = 16, P < 0.01). No such correlation was detected for each single dose of candesartan cilexetil but a dose-response relationship was present when both doses were combined. The pharmacodynamic effects of a single oral dose of 16 mg candesartan cilexetil are greater than those of 50 mg losartan and 8 mg candesartan cilexetil. The variability in the pharmacokinetic-pharmacodynamic interaction is less pronounced for candesartan than for EXP 3174, which could result in reduced variability of the blood pressure effects in patients.
- 1 April 1999
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 17 (4) , 561-568
Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan
The variability of the blood pressure response to blockade of the angiotensin II type 1 receptor is influenced by renin status and pharmacokinetics and pharmacokinetic-Spharmacodynamic interactions. To compare the pharmacokinetic-pharmacodynamic interactions of two doses of an ester prodrug of a noncompetitive angiotensin II type 1 receptor antagonist, candesartan cilexetil, at 8 and 16 mg, with those of the reference angiotenisn II type 1 receptor blocker, losartan, at the standard dose (50 mg), in a human model that controls renin status. In a double-blind placebo-controlled crossover study, we compared the effects on renin and mean blood pressure over 24 h of single oral doses of candesartan cilexetil at 8 and 16 mg and losartan at 50 mg in 16 sodium-depleted normotensive subjects. The area under the curve (0–24 h) for plasma active renin did not differ significantly between 8 mg candesartan cilexetil and 50 mg losartan, but was significantly higher for 16 than for 8 mg candesartan cilexetil or for 50 mg losartan. The area under the curve (0–24 h) for the fall in mean blood pressure with 16 mg candesartan cilexetil (−2197 ± 96 mmHg/h) was significantly greater than that for placebo (−112 ± 81 mmHg/h; P < 0.05) but the difference was not statistically significant compared with either 8 mg candesartan cilexetil (−158 ± 95 mmHg/h) or 50 mg losartan (−144 ± 66 mmHg/h). The area under the curve (0–24 h) for the fall in mean blood pressure did not significantly differ between 8 mg candesartan cilexetil, 50 mg losartan and placebo. The area under the curve (0–24 h) for plasma active renin was significantly correlated to that for plasma levels of the active metabolite of losartan, EXP 3174 (r = 0.65, n = 16, P < 0.01). No such correlation was detected for each single dose of candesartan cilexetil but a dose-response relationship was present when both doses were combined. The pharmacodynamic effects of a single oral dose of 16 mg candesartan cilexetil are greater than those of 50 mg losartan and 8 mg candesartan cilexetil. The variability in the pharmacokinetic-pharmacodynamic interaction is less pronounced for candesartan than for EXP 3174, which could result in reduced variability of the blood pressure effects in patients.